Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBLG FibroBiologics	$0.81 -7.3%	$0.94	$0.70 ▼ $7.77	$30.94M	-0.8	297,068 shs	221,533 shs
KPTI Karyopharm Therapeutics	$4.39 +0.7%	$5.09	$3.51 ▼ $17.40	$37.93M	0.23	81,844 shs	33,104 shs
LTRN Lantern Pharma	$3.05 -5.6%	$3.43	$2.55 ▼ $6.12	$32.89M	1.55	64,046 shs	127,851 shs
MBRX Moleculin Biotech	$0.64 -4.0%	$0.90	$0.40 ▼ $4.90	$9.07M	1.56	1.54 million shs	305,713 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBLG FibroBiologics	-7.31%	-15.41%	-2.74%	-20.72%	-89.43%
KPTI Karyopharm Therapeutics	+0.69%	-2.23%	-9.48%	-34.96%	-71.59%
LTRN Lantern Pharma	-5.57%	-8.13%	-24.88%	-19.74%	-46.02%
MBRX Moleculin Biotech	-3.96%	-4.18%	-35.35%	-43.19%	-85.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FBLG FibroBiologics	3.2649 of 5 stars	3.6	4.0	0.0	2.6	2.5	0.6
KPTI Karyopharm Therapeutics	3.9901 of 5 stars	3.5	1.0	4.6	2.2	2.5	0.6
LTRN Lantern Pharma	2.0658 of 5 stars	3.5	2.0	0.0	1.1	0.8	1.3
MBRX Moleculin Biotech	3.3146 of 5 stars	3.5	5.0	0.0	3.3	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBLG FibroBiologics	3.20	Buy	$13.00	1,507.52% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	884.05% Upside
LTRN Lantern Pharma	3.00	Buy	$25.00	719.67% Upside
MBRX Moleculin Biotech	3.00	Buy	$4.00	523.05% Upside

Current Analyst Ratings Breakdown

Latest MBRX, FBLG, KPTI, and LTRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00
5/15/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
4/9/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/2/2025	LTRN Lantern Pharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
4/1/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/25/2025	MBRX Moleculin Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$4.00
3/24/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$0.04 per share	N/A
KPTI Karyopharm Therapeutics	$142.13M	0.27	N/A	N/A	($1.47) per share	-2.99
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$3.76 per share	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$11.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBLG FibroBiologics	-$16.49M	-$0.21	N/A	N/A	N/A	N/A	N/A	-225.34%	8/6/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$143.10M	-$13.26	N/A	N/A	N/A	-52.62%	N/A	-39.58%	8/5/2025 (Estimated)
LTRN Lantern Pharma	-$15.96M	-$1.84	N/A	N/A	N/A	N/A	-56.91%	-51.17%	8/6/2025 (Estimated)
MBRX Moleculin Biotech	-$29.77M	N/A	0.00	N/A	N/A	N/A	-157.44%	-97.16%	8/4/2025 (Estimated)

Latest MBRX, FBLG, KPTI, and LTRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	LTRN Lantern Pharma	-$0.49	-$0.42	+$0.07	-$0.42	N/A	N/A
5/13/2025	Q1 2025	FBLG FibroBiologics	-$0.10	-$0.14	-$0.04	-$0.14	N/A	N/A
5/13/2025	Q1 2025	MBRX Moleculin Biotech	-$0.71	-$0.69	+$0.02	-$0.69	N/A	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
3/31/2025	Q4 2024	FBLG FibroBiologics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
3/27/2025	Q4 2024	LTRN Lantern Pharma	-$0.51	-$0.54	-$0.03	-$0.54	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBLG FibroBiologics	N/A	1.23	1.23
KPTI Karyopharm Therapeutics	N/A	1.70	2.93
LTRN Lantern Pharma	N/A	8.31	8.31
MBRX Moleculin Biotech	N/A	2.08	2.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBLG FibroBiologics	N/A
KPTI Karyopharm Therapeutics	66.44%
LTRN Lantern Pharma	28.62%
MBRX Moleculin Biotech	15.52%

Insider Ownership

Company	Insider Ownership
FBLG FibroBiologics	20.00%
KPTI Karyopharm Therapeutics	2.98%
LTRN Lantern Pharma	7.31%
MBRX Moleculin Biotech	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBLG FibroBiologics	10	38.26 million	28.84 million	N/A
KPTI Karyopharm Therapeutics	380	8.64 million	122.72 million	Optionable
LTRN Lantern Pharma	20	10.79 million	10.00 million	Optionable
MBRX Moleculin Biotech	20	14.13 million	3.86 million	Not Optionable

MBRX, FBLG, KPTI, and LTRN Headlines

Recent News About These Companies

Q2 Earnings Estimate for MBRX Issued By HC Wainwright

June 13 at 1:21 AM | americanbankingnews.com

Moleculin Biotech announces ‘What This Means’ virtual investor segment

June 12 at 10:51 PM | finance.yahoo.com

Moleculin Biotech, Inc. Reports Positive Topline Results from Phase 1B/2 Trial of Annamycin for Soft Tissue Sarcoma Lung Metastases

June 11 at 10:13 AM | quiverquant.com

Moleculin Participates in Virtual Investor “What This Means” Segment

June 11 at 9:15 AM | globenewswire.com

HC Wainwright Upgrades Moleculin Biotech (NASDAQ:MBRX) to Buy

June 11 at 2:25 AM | americanbankingnews.com

Research Analysts Offer Predictions for MBRX Q4 Earnings

June 11 at 1:33 AM | americanbankingnews.com

Moleculin Biotech Hosts Key Opinion Leaders Event

June 5, 2025 | tipranks.com

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

June 5, 2025 | globenewswire.com

Moleculin Biotech Reports Positive Annamycin Trial Results

June 4, 2025 | msn.com

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

June 4, 2025 | globenewswire.com

Moleculin Biotech files to sell 10.99M shares of common stock, warrants

June 2, 2025 | msn.com

Earnings call transcript: Moleculin Biotech reports Q1 2025 updates

May 15, 2025 | uk.investing.com

MOLECULIN BIOTECH Earnings Results: $MBRX Reports Quarterly Earnings

May 15, 2025 | nasdaq.com

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | globenewswire.com

Moleculin Biotech, Inc.: Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 12, 2025 | finanznachrichten.de

Moleculin Biotech, Inc. Expands Phase 3 Trial of Annamycin for R/R AML to Nine EU Countries, Enrollment Underway

May 12, 2025 | quiverquant.com

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 12, 2025 | globenewswire.com

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 7, 2025 | globenewswire.com

Moleculin secures two new US patents for cancer drug Annamycin

May 6, 2025 | investing.com

Moleculin Biotech, Inc. Announces INN Approval for Annamycin as Pivotal Phase 3 Trial Advances in AML Treatment

May 6, 2025 | quiverquant.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX, FBLG, KPTI, and LTRN Company Descriptions

FibroBiologics NASDAQ:FBLG

$0.81 -0.06 (-7.31%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.82 +0.01 (+1.40%)

As of 06/13/2025 06:07 PM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Karyopharm Therapeutics NASDAQ:KPTI

$4.39 +0.03 (+0.69%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.38 -0.01 (-0.14%)

As of 06/13/2025 07:27 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Lantern Pharma NASDAQ:LTRN

$3.05 -0.18 (-5.57%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.07 +0.02 (+0.66%)

As of 06/13/2025 04:23 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Moleculin Biotech NASDAQ:MBRX

$0.64 -0.03 (-3.96%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.64 +0.00 (+0.47%)

As of 06/13/2025 07:45 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time